This clinical trial is focused on studying a type of prostate cancer known as castration-resistant prostate cancer (CRPC) with a small number of metastases, which are areas where the cancer has spread. The study will explore the effectiveness of a treatment called darolutamide, which is a medication taken as a film-coated tablet. The trial will also investigate whether combining darolutamide with a type of precise radiation treatment called stereotactic body radiation therapy is more effective than using darolutamide alone. The goal is to see if this combination can help patients live longer without the cancer getting worse, as seen on imaging tests.

Participants in the study will receive either darolutamide alone or darolutamide combined with radiation therapy. The study will monitor how the cancer responds to these treatments over time. Other medications that may be used in the study include degarelix, triptorelin, leuprorelin acetate, and goserelin, which are different types of hormone therapies given by injection. These medications help to lower testosterone levels, which can slow the growth of prostate cancer.

The trial aims to determine if the combination of darolutamide and radiation therapy is better at preventing the cancer from progressing compared to darolutamide alone. The study will also look at the safety and side effects of the treatments, as well as their impact on overall survival, quality of life, and other health outcomes. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the effectiveness of the treatments.